Good morning :)
$
₹
Tiziana Life Sciences Ltd

Tiziana Life Sciences Ltd

TLSA

NASDAQ
Asset Logo

Tiziana Life Sciences Ltd

TLSA

NASDAQ
$1.151.31% (+0.01)
$
₹
$1.151.31% (+0.01)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Biotechnology

Micro Cap

With a market cap of $145.1M the stock is ranked 4488

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

2765.43
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.16
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Company Profile

Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom.
Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom.

Peers

Peers

AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
74.63
74.63
1Y Return
28.58%
28.58%
Buy Reco %
57.14
57.14
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
27.32
27.32
1Y Return
54.95%
54.95%
Buy Reco %
46.87
46.87
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
29.44%
29.44%
Buy Reco %
63.33
63.33
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
31.95
31.95
1Y Return
40.79%
40.79%
Buy Reco %
52.94
52.94
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
20.61
20.61
1Y Return
44.92%
44.92%
Buy Reco %
76.00
76.00

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Tiziana Life Sciences Ltd -2765.43-
AbbVie Inc74.6350.450.43
Amgen Inc27.3220.322.30

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

-5.6
-5.6
-12.7
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Revenue
Net Income
Financial YearQ4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026
Total Revenue----------
Net Income-9.07-9.07-9.30-9.30--7.20-5.63-5.63--12.79
Net Profit Margin----------
See CostsAll values in $ Million

Frequently asked questions

Frequently asked questions

  1. What is Tiziana Life Sciences Ltd's share price today?

    Tiziana Life Sciences Ltd (TLSA) share price today is $1.15 as of August 25, 2026 at 1:30 AM IST. The stock touched a day high of $1.21 and a day low of $1.13.

  2. What exchange does Tiziana Life Sciences Ltd stock trade on, and under what ticker symbol?

    Tiziana Life Sciences Ltd stock trades on NASDAQ under the ticker symbol TLSA.

  3. What is Tiziana Life Sciences Ltd's market capitalization?

    Tiziana Life Sciences Ltd's market capitalization is $145.07M as of August 25, 2026 at 1:30 AM IST.

  4. What is Tiziana Life Sciences Ltd's price-to-earnings (P/E) ratio?

    Tiziana Life Sciences Ltd's price-to-earnings (P/E) ratio is N/A as of August 24, 2026.

  5. What is Tiziana Life Sciences Ltd's price-to-book (P/B) ratio?

    Tiziana Life Sciences Ltd's price-to-book (P/B) ratio is 2765.43 as of August 24, 2026.

  6. Can Indian investors buy Tiziana Life Sciences Ltd shares?

    Yes, You can buy Tiziana Life Sciences Ltd shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. How can I invest in Tiziana Life Sciences Ltd shares from India?

    Indian investors can buy Tiziana Life Sciences Ltd shares in three steps: 1. Search Tiziana Life Sciences Ltd on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. How does USD-INR currency movement affect returns from Tiziana Life Sciences Ltd shares for Indian investors?

    Since Tiziana Life Sciences Ltd trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. What is the minimum amount required to invest in Tiziana Life Sciences Ltd shares via Tickertape?

    Indian investors can start investing in Tiziana Life Sciences Ltd (TLSA) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 8.658 shares at the current price of $1.15.

Loading...